Osteoarthritis Therapeutics Market

Osteoarthritis Therapeutics Market Statistics - 2030

The global osteoarthritis therapeutics market size was valued at $6,754.1 million in 2020, and is estimated to reach $15,693.8 million by 2030, growing at a CAGR of 8.8% from 2021 to 2030. Osteoarthritis is one of the most common chronic health conditions characterized by chronic pain and disability with reduced mobility. It is a progressive degenerative disease of joints, caused due to breakdown and eventually loss of cartilage of one or more joints. Cartilage is a connective tissue found in joints between bones such as knees, ankle, and elbow. It helps to provide lubrication and reduce friction in the joint. The goal of osteoarthritis treatment is to elevate the pain and enhance the functional status. 

The COVID-19 outbreak is anticipated to have a negative impact on the growth of the global osteoarthritis therapeutics market. Increase in number of COVID-19 cases and decline in use of non-steroidal anti-inflammatory drugs (NSAIDS) and corticosteroid increase the risk of adverse effects. The COVID-19 pandemic has stressed the healthcare systems in the world and increased the need for development of novel therapeutics.

Growth of the osteoarthritis therapeutics market is majorly driven by increase in prevalence of osteoarthritis; advancements in R&D activities for drug development; increase in funding from private & government organizations for development of healthcare sector and research centers; and rise in demand for cell based research activities. For instance, in 2018, the Journal of Stem cells International announced the new approach for the treatment of osteoarthritis by mesenchyme stem cell therapy. As per the same source, it was reported that there are over 500 clinical trials, which are registered on ClinicalTrails.gov to evaluate the safety and efficacy of adult stem cell such as umbilical cord-derived stem cells, pluripotent stem cells, and mesenchyme stem cells for the treatment of osteoarthritis. 

Rise in number of approval for drug is anticipated to fuel the growth of the infection disease diagnostic market. For instance, in March 2020, the U.S. Food and Drug Administrative (FDA) accepted the regulatory submission for Tanezumab, which is used for the treatment of patient with chronic pain caused due to moderate to severe osteoarthritis.

In addition, rise in geriatric population fuels the osteoarthritis therapeutics market growth, owing to the fact that aged individuals are more susceptible to osteoarthritis. According to the Journal of EClinicalMedicine, in 2020, it was reported that approximately 22% of the population above the age of 40 years are diagnosed with knee osteoarthritis, globally. 

In June 2021, the U.S. Food and Drug Administrative (FDA) announced the approval of CyMedica’s Intellihab system, which is designed for the treatment of pain caused due to debilitating knee osteoarthritis. Thus, technological advancements in osteoarthritis and availability of better treatment option propel the growth of the market. However, high cost of drug used for osteoarthritis and risk associated with the use of nonsteroidal anti-inflammatory drugs, such as stomach ulcer, dizziness, and allergic reaction, are expected to restrict the osteoarthritis therapeutics market growth during the forecast period.

The global osteoarthritis Treatment market segmented into anatomy, drug type, distribution channel, and region. By anatomy, the market is categorized into knee osteoarthritis, hip osteoarthritis, hand osteoarthritis, and small joint osteoarthritis. On the basis of drug type, it is divided into viscosupplementation agents, nonsteroidal anti-inflammatory drugs, analgesics, and corticosteroids. By distribution channel, the market is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Region-wise, the osteoarthritis therapeutics market analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and the rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and the rest of LAMEA).

Segment Review

Depending on anatomy, the knee osteoarthritis segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in prevalence of knee osteoarthritis, advancement in technological development in healthcare sector, increase in geriatric population, and rise in R&D activities in arthritis. However, the hip osteoarthritis segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of obesity, lack of physical activity, and rise in geriatric population.

Top Impacting Factors    

On the basis of drug type, the nonsteroidal anti-inflammatory drugs segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to surge in adoption of NSAIDS drugs, increase in launch of new products, and rise in number of prescriptions. However, the viscosupplementation agents segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of osteoarthritis, advancement in R&D activities for development of new viscosupplementation agents, and initiatives taken by government for development of research activities in healthcare sectors.

By distribution channel, the hospital pharmacies segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to initiatives taken by government for advancement of hospital pharmacy and rise in prevalence of osteoarthritis. However, the online pharmacies segment is expected to witness considerable growth during the forecast period due to advancement in technology in the healthcare sector and rise in demand for remote service.

Europe garnered the major share in the osteoarthritis therapeutics market in 2020, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of knee osteoarthritis, increase in number of approval for osteoarthritis, presence of key players, availability of advanced research activities for drug development, and increase in number of clinical study to evaluate safety and efficacy of drug in the region. However, Asia-Pacific is expected to register the highest CAGR of 9.1% from 2021 to 2030, owing to increase in prevalence of osteoarthritis, rise in number of female population, growth in health care expenditures, and lack of physical activities.

The key players operating in the global osteoarthritis therapeutics market include Abbott Laboratories, Bayer AG, Flexion Therapeutics, Inc., and GlaxoSmithKline plc., Horizon Therapeutics plc., Johnson & Johnson, Novartis, Pfizer Inc., Sanofi, and Zimmer Biomet Holding.

Key Benefits for Stakeholders

• The study provides an in-depth analysis of the osteoarthritis therapeutics market and the current trends & future estimations to elucidate imminent investment pockets.
• It presents a quantitative analysis of the osteoarthritis Treatment market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the osteoarthritis therapeutics market based on procedures and services assists to understand the trends in the industry.
• Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the osteoarthritis therapeutics market.

Key Market Segments

By Anatomy

• Knee Osteoarthritis
• Hip Osteoarthritis
• Hand Osteoarthritis
• Small Joint Osteoarthritis

By Drug Type 

• Viscosupplementation Agents
• Non-steroidal Anti-inflammatory Drugs
• Analgesics
• Corticosteroids

By Distribution Channel

• Hospital Pharmacies
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Small Joint Osteoarthritis
• Retail Pharmacies
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Small Joint Osteoarthritis
• Online Pharmacies
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Small Joint Osteoarthritis

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players 

• Abbott Laboratories
• Bayer AG
• Flexion Therapeutics, Inc.
• GlaxoSmithKline plc.
• Horizon Therapeutics plc.
• Johnson & Johnson
• Novartis
• Pfizer Inc.
• Sanofi
• Zimmer Biomet Holding

 Osteoarthritis Therapeutics Market Report Highlights